Loncastuximab Tesirine PDE report and OEL report profile
Project-specific health-based exposure limit and occupational toxicology assessment support. The agreed scope may include PDE/ADE derivation, OEL derivation and OEB/OHC banding, based on the exact substance form, available evidence and intended product or workplace context.
The anti-CD19 IgG1 antibody binds CD19 on B-lineage cells and is internalised. Proteolytic cleavage releases the SG3199 PBD dimer payload, which binds the DNA minor groove and forms interstrand crosslinks, leading to cell death.
Indications / reported uses
Treatment of adults with relapsed or refractory large B-cell lymphoma after at least two prior systemic treatment lines, under the current product label.
Scope is agreed for the exact substance form, intended use, exposure route, workplace context and available toxicological evidence.
PDE/ADE: critical effects, point of departure and justified adjustment factors.
OEL: inhalation hazards, exposure duration and workplace conditions.
OEB/OHC: evidence-based banding where requested; a band is not a numerical OEL.
Report: scientific rationale, source data, assumptions, uncertainties and limitations.
Assessment scope
PDE/ADE and OEL/OEB assessment
ReguSight provides project-specific support for Loncastuximab Tesirine PDE/ADE, OEL and OEB/OHC assessments. This combined profile covers the Loncastuximab Tesirine Permitted Daily Exposure (PDE) report (the Loncastuximab Tesirine PDE report); Acceptable Daily Exposure (ADE) is the corresponding health-based daily exposure terminology. It also covers the Loncastuximab Tesirine Occupational Exposure Limit (OEL) report (the Loncastuximab Tesirine OEL report). PDE/ADE derivation and workplace exposure assessment are distinct scientific outputs; a band is not a numerical OEL.
Assessment may cover
PDE/ADE derivation using relevant toxicological evidence, critical effects, a justified point of departure and adjustment factors.
The EMA HBEL guideline informs PDE/ADE assessments in relevant shared-facility contexts. ECHA and HSE sources address workplace exposure limits; NIOSH provides occupational exposure-banding guidance. The applicable framework depends on the assessment question and jurisdiction.